OncoRep: an n-of-1 reporting tool to support genome-guided treatment for breast cancer patients using RNA-sequencing
暂无分享,去创建一个
Andrew I Su | Kathleen M Fisch | Tobias Meißner | Louis Gioia | A. Su | T. Meissner | Louis Gioia | Fisch Kathleen M.
[1] Jun Li,et al. A cost-effective and universal strategy for complete prokaryotic genome sequencing proposed by computer simulation , 2011, Genome Biology.
[2] Davis J. McCarthy,et al. Count-based differential expression analysis of RNA sequencing data using R and Bioconductor , 2013, Nature Protocols.
[3] L. De Mattos-Arruda,et al. Pilot studies for personalized cancer medicine: focusing on the patient for treatment selection. , 2013, The oncologist.
[4] J. Rosen,et al. Modelling breast cancer: one size does not fit all , 2007, Nature Reviews Cancer.
[5] Jin Billy Li,et al. Reliable identification of genomic variants from RNA-seq data. , 2013, American journal of human genetics.
[6] A. Sivachenko,et al. Sequence analysis of mutations and translocations across breast cancer subtypes , 2012, Nature.
[7] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[8] Gabriele Sales,et al. graphite - a Bioconductor package to convert pathway topology to gene network , 2012, BMC Bioinformatics.
[9] David S. Wishart,et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..
[10] Thomas R. Gingeras,et al. STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..
[11] P. Edwards,et al. Are breast cancers driven by fusion genes? , 2012, Breast Cancer Research.
[12] Pablo Cingolani,et al. © 2012 Landes Bioscience. Do not distribute. , 2022 .
[13] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[14] J. Ross,et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. , 2009, The oncologist.
[15] Deanna M. Church,et al. ClinVar: public archive of relationships among sequence variation and human phenotype , 2013, Nucleic Acids Res..
[16] F. André,et al. mTOR inhibitors in advanced breast cancer: ready for prime time? , 2013, Cancer treatment reviews.
[17] J. Reis-Filho,et al. Histological and molecular types of breast cancer: is there a unifying taxonomy? , 2009, Nature Reviews Clinical Oncology.
[18] A. Ashworth,et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.
[19] Liliana Florea,et al. Transcriptomic landscape of breast cancers through mRNA sequencing , 2012, Scientific Reports.
[20] R. Natrajan,et al. From integrative genomics to therapeutic targets. , 2013, Cancer research.
[21] Mingming Jia,et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..
[22] Andrew I. Su,et al. Omics Pipe: A Computational Framework for Reproducible Multi-Omics Data Analysis , 2014, bioRxiv.
[23] S. Fuqua,et al. RNA sequencing of cancer reveals novel splicing alterations , 2013, Scientific Reports.
[24] Paolo G. V. Martini,et al. PANP - a New Method of Gene Detection on Oligonucleotide Expression Arrays , 2007, 2007 IEEE 7th International Symposium on BioInformatics and BioEngineering.
[25] J. Shendure,et al. A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.
[26] Michael P. Schroeder,et al. IntOGen-mutations identifies cancer drivers across tumor types , 2013, Nature Methods.
[27] S. Fuqua,et al. Novel Insights into Breast Cancer Genetic Variance through RNA Sequencing , 2013, Scientific Reports.
[28] Peter Dalgaard,et al. R Development Core Team (2010): R: A language and environment for statistical computing , 2010 .
[29] Rainer Spang,et al. Microarray Based Diagnosis Profits from Better Documentation of Gene Expression Signatures , 2008, PLoS Comput. Biol..
[30] A. Børresen-Dale,et al. Identification of fusion genes in breast cancer by paired-end RNA-sequencing , 2011, Genome Biology.
[31] R. Altman,et al. Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.
[32] A. Jemal,et al. Global Cancer Statistics , 2011 .
[33] Martin Krapcho,et al. SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations) , 2012 .
[34] Jean YH Yang,et al. Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.
[35] Pooja Mittal,et al. A novel signaling pathway impact analysis , 2009, Bioinform..
[36] Paul Theodor Pyl,et al. HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.
[37] W. Huber,et al. which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .
[38] Mikhail Shugay,et al. Oncofuse: a computational framework for the prediction of the oncogenic potential of gene fusions , 2013, Bioinform..
[39] Benjamin M. Good,et al. Organizing knowledge to enable personalization of medicine in cancer , 2014, Genome Biology.
[40] Marian Kelley,et al. One size does not fit all. , 2011, Bioanalysis.
[41] R. Tibshirani,et al. Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[42] C. Elsik. The pea aphid genome sequence brings theories of insect defense into question , 2010, Genome Biology.
[43] E. Boerwinkle,et al. dbNSFP v2.0: A Database of Human Non‐synonymous SNVs and Their Functional Predictions and Annotations , 2013, Human mutation.
[44] Melissa Bondy,et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. , 2008, Journal of the National Cancer Institute.